Resources from the same session
LBA38 - Iparomlimab and tuvonralimab (QL1706) with bevacizumab and/or chemotherapy in first-line (1L) treatment of advanced hepatocellular carcinoma (aHCC): A randomized, open-label, phase II/III study (DUBHE-H-308)
Presenter: Shukui Qin
Session: Proffered paper session 1: GI tumours, upper digestive
Resources:
Abstract
Slides
Webcast
LBA39 - Updated efficacy and safety data from IMbrave050: Phase III study of adjuvant atezolizumab (atezo) + bevacizumab (bev) vs active surveillance in patients (pts) with resected or ablated high-risk hepatocellular carcinoma (HCC)
Presenter: Adam Yopp
Session: Proffered paper session 1: GI tumours, upper digestive
Resources:
Abstract
Slides
Webcast
Invited Discussant LBA38 and LBA39
Presenter: Maeve Lowery
Session: Proffered paper session 1: GI tumours, upper digestive
Resources:
Slides
Webcast
Q&A
Session: Proffered paper session 1: GI tumours, upper digestive
Resources:
Webcast
LBA62 - Preoperative modified FOLFIRINOX (mFOLFIRINOX) with or without chemoradiation (CRT) in borderline resectable pancreatic cancer (BRPC): Results from the randomized phase II trial PANDAS/PRODIGE 44
Presenter: Aurélien Lambert
Session: Proffered paper session 1: GI tumours, upper digestive
Resources:
Abstract
Slides
Webcast
LBA40 - Primary results from the phase III ALTN-AK105-III-02 study: Anlotinib plus penpulimab versus sorafenib as first-line (1L) therapy for advanced hepatocellular carcinoma (aHCC)
Presenter: Jian Zhou
Session: Proffered paper session 1: GI tumours, upper digestive
Resources:
Abstract
Slides
Webcast
Invited Discussant LBA62 and LBA40
Presenter: Rachna Shroff
Session: Proffered paper session 1: GI tumours, upper digestive
Resources:
Slides
Webcast